Abstract
Repeated hepatectomy is the standard of care for resectable recurrent hepatocellular carcinoma (rHCC) whose recurrence rate remains higher than primary HCC. Moreover, there is no solid perioperative therapy for rHCC. This trial aims to assess the efficacy and safety of neoadjuvant tislelizumab in rHCC patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
